Q-Line Biotech's ₹214 crore IPO subscribed 2.33 times on day one
What's the deal? Indian healthcare solutions provider Q-Line Biotech opened its initial public offering on May 21, and the issue was already subscribed 2.33 times within hours. The company received bids for over 1.04 crore shares against 44.72 lakh on offer, according to NSE data.
The ₹214.48 crore IPO is entirely a fresh issue of 62.53 lakh shares priced at ₹326 to ₹343 per share. Q-Line plans to use the proceeds for working capital, debt repayment, and general corporate purposes.
The subscription window runs until May 25, with shares expected to list on NSE's SME platform, Emerge, on May 29.
Why now? Q-Line Biotech develops, manufactures, and markets diagnostic reagents, point-of-care devices, and diagnostic equipment. The company posted revenue of ₹313.78 crore and profit after tax of ₹28.13 crore in FY 2024–25 — a financial profile that appears to have attracted strong investor interest.
Before the IPO opened, Q-Line raised ₹61.09 crore from anchor investors including Abakkus Mutual Fund, Bharat Venture Opportunities Fund, Carnelian Capital, 360 ONE, and HDFC BankDealroom has a profile for this one. Try Dealroom →, all at the upper price band of ₹343.
What could go wrong? Grey market indicators suggest bullish sentiment — unlisted shares are reportedly trading at ₹486, a 42% premium over the IPO price. But grey market premiums are unofficial and unregulated by SEBI or stock exchanges, meaning they can shift quickly and don't guarantee listing-day performance.
The minimum investment requires two lots (800 shares), which at the upper band totals ₹274,400 — a meaningful commitment for retail investors in a small-cap IPO on an SME platform.
The signal: The anchor round's mix of institutional names — from wealth manager 360 ONE to corporate investor HDFC Bank — underscores how India's established financial players are increasingly backing diagnostics and healthcare companies at the IPO stage. With Q-Line's revenue already above ₹300 crore and the issue oversubscribed on day one, the listing will be a bellwether for whether the SME Emerge platform can continue to channel mainstream capital into smaller healthcare manufacturers.
Read more: upstox.com
